Cost-Effectiveness of Dabigatran (150 Mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation

American Journal of Cardiology - United States
doi 10.1016/j.amjcard.2015.09.048
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Practical Guide to Choosing Dabigatran 150 Mg Twice Daily or Apixaban 5 Mg Twice Daily for Patients With Atrial Fibrillation

Journal of Rural Medicine
2019English

Cost-Effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation

Archives of Internal Medicine
1998English

Cost-Effectiveness Analysis of Apixaban Against Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation in Japan

Clinical Therapeutics
Pharmacology
2015English

Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2011English

Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Yearbook of Cardiology
2012English

Effectiveness and Safety of 110 or 150 Mg Dabigatran Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation.

British Journal of Clinical Pharmacology
Pharmacology
2018English

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion

Circulation
Cardiovascular MedicinePhysiologyCardiology
2011English

Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin

Archives of Internal Medicine
2006English

Comparative Effectiveness and Safety of Warfarin and Dabigatran in Patients With Non-Valvular Atrial Fibrillation in Japan: A Claims Database Analysis

Journal of Cardiology
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy